Pergolide, a potent long-acting dopamine-receptor agonist

Louis Lemberger, Ross Crabtree, John Callaghan

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

After single doses (100 to 400 μg orally), pergolide, a synthetic ergot, reduced basal plasma prolactin levels in normal subjects in a dose-related manner. This effect persisted for more than 24 hr. Multiple doses of pergolide (150 to 250 μg daily for 7 days) resulted in a plasma prolactin decrease of more than 80%. A single dose of pergolide (150 μg orally) suppressed plasma prolactin and abolished the plasma prolactin diurnal rhythm, i.e., suppression of sleep-induced elevation in plasma prolactin during a 40-hr period. Perphenazine (5 mg intramuscularly)-induced plasma prolactin elevation was inhibited by pergolide; the effect was dose dependent. After single or multiple doses, pergolide had no effect on plasma follicle-stimulating hormone, luteinizing hormone, cortisol, growth hormone, and thyroid-stimulating hormone. Pergolide appears to have .specificity at the pituitary, level for the dopamine receptors that mediate prolactin secretion.

Original languageEnglish
Pages (from-to)642-651
Number of pages10
JournalClinical Pharmacology and Therapeutics
Volume27
Issue number5
StatePublished - May 1980

Fingerprint

Pergolide
Dopamine Agonists
Prolactin
Perphenazine
Dopamine Receptors
Follicle Stimulating Hormone
Thyrotropin
Luteinizing Hormone
Circadian Rhythm
Growth Hormone
Hydrocortisone
Sleep

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pergolide, a potent long-acting dopamine-receptor agonist. / Lemberger, Louis; Crabtree, Ross; Callaghan, John.

In: Clinical Pharmacology and Therapeutics, Vol. 27, No. 5, 05.1980, p. 642-651.

Research output: Contribution to journalArticle

Lemberger, Louis ; Crabtree, Ross ; Callaghan, John. / Pergolide, a potent long-acting dopamine-receptor agonist. In: Clinical Pharmacology and Therapeutics. 1980 ; Vol. 27, No. 5. pp. 642-651.
@article{301d7bed60bb412697877b5a137b16f5,
title = "Pergolide, a potent long-acting dopamine-receptor agonist",
abstract = "After single doses (100 to 400 μg orally), pergolide, a synthetic ergot, reduced basal plasma prolactin levels in normal subjects in a dose-related manner. This effect persisted for more than 24 hr. Multiple doses of pergolide (150 to 250 μg daily for 7 days) resulted in a plasma prolactin decrease of more than 80{\%}. A single dose of pergolide (150 μg orally) suppressed plasma prolactin and abolished the plasma prolactin diurnal rhythm, i.e., suppression of sleep-induced elevation in plasma prolactin during a 40-hr period. Perphenazine (5 mg intramuscularly)-induced plasma prolactin elevation was inhibited by pergolide; the effect was dose dependent. After single or multiple doses, pergolide had no effect on plasma follicle-stimulating hormone, luteinizing hormone, cortisol, growth hormone, and thyroid-stimulating hormone. Pergolide appears to have .specificity at the pituitary, level for the dopamine receptors that mediate prolactin secretion.",
author = "Louis Lemberger and Ross Crabtree and John Callaghan",
year = "1980",
month = "5",
language = "English",
volume = "27",
pages = "642--651",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Pergolide, a potent long-acting dopamine-receptor agonist

AU - Lemberger, Louis

AU - Crabtree, Ross

AU - Callaghan, John

PY - 1980/5

Y1 - 1980/5

N2 - After single doses (100 to 400 μg orally), pergolide, a synthetic ergot, reduced basal plasma prolactin levels in normal subjects in a dose-related manner. This effect persisted for more than 24 hr. Multiple doses of pergolide (150 to 250 μg daily for 7 days) resulted in a plasma prolactin decrease of more than 80%. A single dose of pergolide (150 μg orally) suppressed plasma prolactin and abolished the plasma prolactin diurnal rhythm, i.e., suppression of sleep-induced elevation in plasma prolactin during a 40-hr period. Perphenazine (5 mg intramuscularly)-induced plasma prolactin elevation was inhibited by pergolide; the effect was dose dependent. After single or multiple doses, pergolide had no effect on plasma follicle-stimulating hormone, luteinizing hormone, cortisol, growth hormone, and thyroid-stimulating hormone. Pergolide appears to have .specificity at the pituitary, level for the dopamine receptors that mediate prolactin secretion.

AB - After single doses (100 to 400 μg orally), pergolide, a synthetic ergot, reduced basal plasma prolactin levels in normal subjects in a dose-related manner. This effect persisted for more than 24 hr. Multiple doses of pergolide (150 to 250 μg daily for 7 days) resulted in a plasma prolactin decrease of more than 80%. A single dose of pergolide (150 μg orally) suppressed plasma prolactin and abolished the plasma prolactin diurnal rhythm, i.e., suppression of sleep-induced elevation in plasma prolactin during a 40-hr period. Perphenazine (5 mg intramuscularly)-induced plasma prolactin elevation was inhibited by pergolide; the effect was dose dependent. After single or multiple doses, pergolide had no effect on plasma follicle-stimulating hormone, luteinizing hormone, cortisol, growth hormone, and thyroid-stimulating hormone. Pergolide appears to have .specificity at the pituitary, level for the dopamine receptors that mediate prolactin secretion.

UR - http://www.scopus.com/inward/record.url?scp=0018838138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018838138&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 642

EP - 651

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -